Business Wire

MA-NETSCOUT-SYSTEMS

25.4.2024 12:06:33 CEST | Business Wire | Press release

Share
Geopolitical Unrest Generates an Onslaught of DDoS Attacks, According to the Latest NETSCOUT Threat Intelligence Report

NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) today released findings from its 2H2023 DDoS Threat Intelligence Report that dissects trends and attack methodologies adversaries use against service providers, enterprises, and end-users. The information cited in the report is gathered from NETSCOUT’s unparalleled internet visibility at a global scale, collecting, analyzing, prioritizing, and disseminating data on DDoS attacks from 214 countries and territories, 456 vertical industries, and more than 13,000 Autonomous System Numbers (ASNs). Driven by tech-savvy and politically motivated hacktivist groups and an increase in DNS water torture attacks, NETSCOUT observed more than 7 million DDoS attacks in the second half of 2023, representing a 15% increase from the first half.

Hacktivism Increases Ten-Fold

DDoS (Distributed Denial-of-Service) hacktivism transcended geographic borders during the past year, exemplifying a shift in the global security landscape. Groups like NoName057(016) and Anonymous Sudan, as well as lone hackers and small collectives, are increasingly using DDoS to target those ideologically opposed to them, for example:

  • Peru experienced a 30% increase in attacks tied to protests of former Peruvian President Fujimori’s release from prison on December 6.
  • Poland experienced a surge in attacks at the end of 2023 associated with a regime change and statements reaffirming Poland’s support of Ukraine in the Russia-Ukraine conflict.
  • Anonymous Sudan attacked X (formerly Twitter) to influence Elon Musk regarding Starlink service in Sudan, and it attacked Telegram for suspending its main channel.

NoName057(016), Anonymous Sudan, and Killnet have taken credit for DDoS attacks in Ukraine, Russia, Israel, and Palestine targeting communications infrastructure, hospitals, and banks. Daily attacks from hacktivists increased more than ten-fold between the first and second halves of 2023. NoName057(016) topped the list of DDoS adversaries in 2023, targeting 780 websites across 35 countries.

Water Torture Attacks Rise

Targeting critical systems at the heart of the Internet's control plane, DNS (Domain Name System) water torture attacks have been on the rise since the end of 2019. DNS query floods designed to overwhelm authoritative DNS servers experienced a massive 553% increase from 1H2020 to 2H2023. Rather than targeting one website or server, adversaries go after entire systems, resulting in even more damage.

Gaming and Gambling Targeted

NETSCOUT findings point to gaming -- and the gambling associated with gaming – as a primary target for DDoS attacks. Threat actors are drawn to the sector’s substantial financial value and the goal of disrupting competitors, especially during online esports tournaments. Historically, 80-90% of all DDoS attacks are related to gaming and gambling. NETSCOUT assessed attacks on enterprises in these sectors, determining that more than 100,000 DDoS attacks were deployed against those in gaming, and over 20,500 were made against those tied to gambling in 2023.

In addition, based on NETSCOUT’s observations of the DDoS threat landscape, approximately 1% of DDoS attacks are suppressed from originating networks.

“Global adversaries have become more sophisticated in the past year attacking websites and overloading servers to lockout customers and inflict digital chaos to influence geopolitical issues,” stated Richard Hummel, senior threat intelligence lead, NETSCOUT. “The relentless barrage of DDoS threats drives up costs and creates security fatigue for network operators. They cannot safeguard their digital assets without the proper advanced DDoS protection leveraging predictive, real-time threat intelligence.”

Multiple decades of experience working with the world’s largest service providers and enterprises give NETSCOUT far-reaching visibility into the global internet to discern the pulse of the digital world. Our capacity to monitor and respond to DDoS attacks is powered by our ATLAS platform, which enables us to analyze an impressive 500 terabits per second (Tbps) of network traffic.

Visit our interactive website for more information on NETSCOUT's DDoS Threat Intelligence Report. For real-time DDoS attack stats, map, and insights, visit NETSCOUT Cyber Threat Horizon.

About NETSCOUT

NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) protects the connected world from cyberattacks and performance and availability disruptions through the company’s unique visibility platform and solutions powered by its pioneering deep packet inspection at scale technology. NETSCOUT serves the world’s largest enterprises, service providers, and public sector organizations. Learn more at www.netscout.com or follow @NETSCOUT on LinkedIn, X, or Facebook.

©2024 NETSCOUT SYSTEMS, INC. All rights reserved. NETSCOUT, the NETSCOUT logo, Guardians of the Connected World, Visibility Without Borders, Adaptive Service Intelligence, Arbor, ATLAS, Cyber Threat Horizon, InfiniStream, nGenius, nGeniusONE, Omnis, and TrueCall are registered trademarks or trademarks of NETSCOUT SYSTEMS, INC., and/or its subsidiaries and/or affiliates in the USA and/or other countries. Third-party trademarks mentioned are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240425443965/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye